Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221578 | 1.00 | DHODH (0.50) | DHODHPTGS2SYKMGLLMEN1 | |
| SCHEMBL4220313 | 0.87 | TP53 (0.43) | DHODHPTGS2MGLLMEN1KMT2A | |
| SCHEMBL4220316 | 0.87 | TP53 (0.43) | DHODHPTGS2MGLLMEN1KMT2A | |
| SCHEMBL4220307 | 0.87 | TP53 (0.43) | DHODHPTGS2MGLLMEN1KMT2A | |
| SCHEMBL4217379 | 0.85 | DHODH (0.41) | DHODHSYKMEN1KMT2ATP53 | |
| SCHEMBL4217374 | 0.85 | DHODH (0.41) | DHODHSYKMEN1KMT2ATP53 | |
| SCHEMBL4210723 | 0.83 | DHODH (0.53) | DHODHSYKMEN1KMT2AITGB3 | |
| SCHEMBL4210720 | 0.83 | DHODH (0.53) | DHODHSYKMEN1KMT2AITGB3 | |
| SCHEMBL4213907 | 0.82 | DHODH (0.52) | DHODHSYKMGLLMEN1KMT2A | |
| SCHEMBL4222173 | 0.82 | DHODH (0.52) | DHODHPTGS2SYKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383652-B2 | Biaromatic compounds that modulate PPAR-receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-08 | — | — | US | disclosed |
| EP-1943213-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | Galderma Research & Development (FR) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007049158-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | PPARG, PPARD, PPARA | DHODH 2932/4885PTGS2 1120/4885SYK 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.